Abstract:The canonical Wnt signaling pathway is involved in a variety of biological processes like cell proliferation, cell polarity, and cell fate determination. This pathway has been extensively investigated as its deregulation is linked to different diseases, including various types of cancer, skeletal defects, birth defect disorders (including neural tube defects), metabolic diseases, neurodegenerative disorders and several fibrotic diseases like desmoid tumors. In the "on state", beta-catenin, the key effector of Wnt signaling, enters the nucleus where it binds to the members of the TCF-LEF family of transcription factors and exerts its effect on gene transcription. Disease development can be caused by direct or indirect alterations of the Wnt/β-catenin signaling. In the first case germline or somatic mutations of the Wnt components are associated to several diseases such as the familial adenomatous polyposis (FAP) - caused by germline mutations of the tumor suppressor adenomatous polyposis coli gene (APC) - and the desmoid-like fibromatosis, a sporadic tumor associated with somatic mutations of the β-catenin gene (CTNNB1). In the second case, epigenetic modifications and microenvironmental factors have been demonstrated to play a key role in Wnt pathway activation. The natural autocrine Wnt signaling acts through agonists and antagonists competing for the Wnt receptors. Anomalies in this regulation, whichever is their etiology, are an important part in the pathogenesis of Wnt pathway linked diseases. An example is promoter hypermethylation of Wnt antagonists, such as SFRPs, that causes gene silencing preventing their function and consequently leading to the activation of the Wnt pathway. Microenvironmental factors, such as the extracellular matrix, growth factors and inflammatory mediators, represent another type of indirect mechanism that influence Wnt pathway activation. A favorable microenvironment can lead to aberrant fibroblasts activation and accumulation of ECM proteins with subsequent tissue fibrosis that can evolve in fibrotic disease or tumor. Since the development and progression of several diseases is the outcome of the Wnt pathway cross-talk with other signaling pathways and inflammatory factors, it is important to consider not only direct inhibitors of the Wnt signaling pathway but also inhibitors of microenvironmental factors as promising therapeutic approaches for several tumors of fibrotic origin.

[Crosstalk Between Canonical TGF-β/Smad and Wnt/β-catenin Signaling Pathway].

Tgf-Beta and Bmp Signaling in Osteoblast, Skeletal Development, and Bone Formation, Homeostasis and Disease

Transforming Growth Factor-β Signaling in Fibrotic Diseases and Cancer-Associated Fibroblasts

TGF-β signaling: critical nexus of fibrogenesis and cancer

Wnt/beta-catenin signaling: a promising new target for fibrosis diseases.

Targeting TGF-β signal transduction for fibrosis and cancer therapy

Signaling cross-talk between TGF-β/BMP and other pathways

Transforming Growth Factor- Signaling in Fibrotic Diseases and Cancer-Associated Fibroblasts

Signal Transduction Pathways of EMT Induced by TGF-β, SHH, and WNT and Their Crosstalks

Wnt/β-catenin Singal Transduction Pathway and Colorectal Cancer

TGF-β Signaling in Cell Fate Control and Cancer.

Crosstalk between Wnt/β-Catenin and NF-κB Signaling Pathway during Inflammation

TGF-β signaling in cell fate control and cancer

Convergence Between Wnt-β-catenin and EGFR Signaling in Cancer

The Wnt/β-catenin pathway in human fibrotic-like diseases and its eligibility as a therapeutic target

[Crosstalk of Hippo/YAP and Wnt/β-catenin Pathways].

Wnt/β-catenin signaling pathway in carcinogenesis and cancer therapy

Transforming Growth Factor Β Signaling Pathway: A Promising Therapeutic Target for Cancer

β-Catenin Signaling in Fibroproliferative Disease

Crosstalk between Wnt/β-catenin and Hedgehog/Gli signaling pathways in colon cancer and implications for therapy.

TGF-β Signaling from Receptors to Smads